Immuno-Oncology Drugs Segment Is The Largest Segment Driving The Growth Of Head And Neck Cancer Drugs Market


The global Head and Neck Cancer Drugs Market is estimated to be valued at US$ 1,986.3 Mn in 2023 and is expected to exhibit a CAGR of 7.3% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.


Market Overview:
Head and neck cancer refers to a group of cancers that start in the mouth, nose, throat, larynx, sinuses, or salivary glands. Head and neck cancer drugs are used for treating head and neck cancers and aim to destroy or slow the growth of cancer cells. These include surgery, radiation therapy, chemotherapy, and targeted therapies.

Market key trends:
One of the key trends in the head and neck cancer drugs market is the rising adoption of biologics. Biologics are medications made from living organisms or contain components of living organisms. They are complex molecules that are much larger than chemicals derived from petrochemicals. Targeted biologic therapies aim to block the growth and spread of cancer by interfering with specific molecules involved in tumor growth and progression. Examples of biologic therapies used in head and neck cancer include cetuximab and nivolumab that have demonstrated survival benefits. The biologics segment is expected to witness highest growth in the head and neck cancer drugs market owing to growing demand for personalized treatment and preference for therapies with greater efficacy and fewer side effects.

Segment Analysis
The head and neck cancer drugs market is segmented by type, application, distribution channel, and geography. Based on type, the market is segmented into PD inhibitors, microtubule inhibitors, and others. The PD inhibitors segment dominated the market with a share of more than 45% in 2022 due to the high efficacy and success rate of PD-1/PD-L1 inhibitors for treating head and neck cancer. By application, the market is segmented into oral cancer, laryngeal cancer, salivary gland cancer, and others. The oral cancer segment held the largest share of more than 35% in 2022 owing to the high prevalence of oral cancer worldwide.

Key Takeaways
The Global Head And Neck Cancer Drugs Market Size is expected to witness high growth, exhibiting CAGR of 7.3% over the forecast period, due to increasing prevalence of head and neck cancers worldwide.

Regional analysis
North America dominated the global market in 2022 and is expected to continue its dominance over the forecast period. This is attributed to the increasing healthcare expenditure and significant product availability in the region. Asia Pacific is expected to grow at the fastest CAGR during the forecast period owing to rising healthcare awareness and improving healthcare infrastructure in emerging economies such as China and India.

Key players
Key players operating in the head and neck cancer drugs market are Merck & Co., Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Astrazeneca Plc., Fresenius Medical Care AG & CO. KGAA, and F. Hoffmann-la Roche Ltd. (Genentech, Inc.), among others. Merck & Co., Inc. is one of the leading players with its strong PD-1 inhibitor, Keytruda, which has proven to be highly effective against head and neck cancers.

Read More: https://www.ukwebwire.com/head-and-neck-cancer-drugs-market-size-share-and-growth-forecast-2023-2023/

Comments

Popular posts from this blog

Petroleum Coke (Petcoke) in Electricity Generation is Fueling Growth of Petroleum Coke Market

Surgical Instrument Tracking Market is Estimated To Witness High Growth Owing To Traceability and Sterility trends

Network Automation Market Witnesses Ongoing Developments in AI and Machine Learning Segment Is Fueling Network Automation Market Growth